sorafenib has been researched along with npi 2358 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (npi 2358) | Trials (npi 2358) | Recent Studies (post-2010) (npi 2358) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 36 | 4 | 31 |
| Protein | Taxonomy | sorafenib (IC50) | npi 2358 (IC50) |
|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.8 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.8 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 8.9 | |
| Mitogen-activated protein kinase 10 | Rattus norvegicus (Norway rat) | 6.8 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.4 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, M; Li, L; Li, W; Yuan, S; Zhao, J | 1 |
1 other study(ies) available for sorafenib and npi 2358
| Article | Year |
|---|---|
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diketopiperazines; Drug Synergism; Humans; Liver Neoplasms; Mice, Nude; Microtubules; Sorafenib; Xenograft Model Antitumor Assays | 2018 |